Dr. Clay Siegall Shares How He Made Seattle Genetics Successful
Clay Siegall is the famed CEO and founder of Seattle Genetics. In an interview, he shared some personal secrets to success and a look into his successful career. He was always interested in medicine and how it can be used to improve life and turn around a life of someone that is sick. He first got interested in cancer treatment when a member of his family was sick and almost died — from the chemotherapy, not from the cancer. This showed him that there must be a way to find better treatments for cancer. That’s how he eventually got into Seattle Genetics.
At Seattle Genetics, they develop drugs that can help provide cures to cancer and other illnesses. Getting a drug approved by the FDA is a very long process and a huge achievement. After all, only around ten percent of drug applications actually get approved by the FDA. However, Seattle Genetics has many drugs approved by the FDA. For example, they have their antibody drug conjugate. This is actually the first antibody drug conjugate ever approved by the FDA! It’s approved for three indications.
Seattle Genetics is always doing seven to eight figure deals. They get their deals through meetings, connections and networking. They also have the best lawyers on their team. They have an amazing sales team. Clay Siegall thinks that what makes him successful and what makes Seattle Genetics successful is one thing: Hard work. People are always the same, and what differentiates between them is hard work.
In particular, Seattle Genetics focuses on developing drugs for conditions that have not seen an improvement yet in recent years in regards to mortality rates. He studied at the University of Maryland and George Washington University. He has a Ph.D. in genetics and a B.S. in zoology.
Seattle Genetics has a line of over twenty drugs. They are partnered with the major drug companies such as Pfizer. He grew Seattle Genetics from a small company to a major leader in the field of cancer drug treatment. Dr. Siegall has also worked at the Bristol Myers Squibb Pharmaceutical Research Institute as well as the National Cancer Institute.